{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T02:29:18Z","timestamp":1774060158458,"version":"3.50.1"},"reference-count":54,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Actas Dermo-Sifiliogr\u00e1ficas"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1016\/j.ad.2017.11.009","type":"journal-article","created":{"date-parts":[[2018,2,9]],"date-time":"2018-02-09T01:16:41Z","timestamp":1518139001000},"page":"323-330","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Dermatolog\u00eda e inmunoglobulinas. \u00bfA qui\u00e9n y c\u00f3mo administrarlas?"],"prefix":"10.1016","volume":"109","author":[{"given":"F.J.","family":"Navarro-Trivi\u00f1o","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"P\u00e9rez-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Ru\u00edz-Villaverde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ad.2017.11.009_bib0275","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.jaci.2016.09.023","article-title":"Update on the use of immunoglobulin in human disease: A review of evidence","volume":"139","author":"P\u00e9rez","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.ad.2017.11.009_bib0280","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1056\/NEJM199312303292704","article-title":"A controlled trial of high-dose intravenous immune infusions as treatment for dermatomyositis","volume":"27","author":"Dalakas","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ad.2017.11.009_bib0285","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1002\/art.20078","article-title":"Quality of myositis. Case reports open to improvement","volume":"51","author":"Van de Vlekkert","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ad.2017.11.009_bib0290","first-page":"CD003643","article-title":"Immunosuppressant and immunomodulatory treatment for dermatomyositis and polymyositis","volume":"8","author":"Gordon","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ad.2017.11.009_bib0295","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1136\/adc.72.1.25","article-title":"Intravenous immunoglobulin in juvenile dermatomyositis-four year review of nine cases","volume":"72","author":"Sansome","year":"1995","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.ad.2017.11.009_bib0300","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1111\/jdv.12223","article-title":"Clinical efficacy of intravenous immunoglobulins for the treatment of dermatomyositis skin lesions without muscle disease","volume":"28","author":"Bounfour","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2017.11.009_bib0305","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.jaad.2015.03.047","article-title":"Intravenous immunoglobulin for treatment of dermatomiosistis-associated dystrophic calcinosis","volume":"73","author":"Galimberti","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2017.11.009_bib0310","first-page":"2012","article-title":"Refractory calcinosis in a patient with dermatomyositis: response to intravenous immune globulin","volume":"18","author":"Shahani","year":"2012","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.ad.2017.11.009_bib0315","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.annder.2015.10.594","article-title":"Severe edematous dermatomyositis","volume":"143","author":"Goussot","year":"2016","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.ad.2017.11.009_bib0320","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1111\/ajd.12172","article-title":"Dermatomyositis panniculitis: A case report","volume":"56","author":"Carroll","year":"2015","journal-title":"Australas J Dermatol"},{"key":"10.1016\/j.ad.2017.11.009_bib0325","article-title":"Treatment of clinically amyopathic dermatomyositis in adults: A systematic review","author":"Callander","year":"2016","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2017.11.009_bib0330","doi-asserted-by":"crossref","first-page":"77","DOI":"10.2174\/1874312901409010077","article-title":"Intravenous immune globulin in amyopathic dermatomyositis-report of two cases and review of the literature","volume":"9","author":"Cafardi","year":"2015","journal-title":"Open Rheumatol J"},{"key":"10.1016\/j.ad.2017.11.009_bib0335","doi-asserted-by":"crossref","first-page":"e19","DOI":"10.3928\/19382359-20161214-01","article-title":"Intravenous immunoglobulin in pediatric rheumatology: When to use it and what is the evidence","volume":"46","author":"Rodriguez","year":"2017","journal-title":"Pediatr Ann"},{"key":"10.1016\/j.ad.2017.11.009_bib0340","doi-asserted-by":"crossref","first-page":"e20153537","DOI":"10.1542\/peds.2015-3537","article-title":"Subcutaneous immunoglobulin in refractory juvenile dermatomyositis","volume":"137","author":"De Inocencio","year":"2016","journal-title":"Pediatrics"},{"key":"10.1016\/j.ad.2017.11.009_bib0345","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.jaad.2008.09.052","article-title":"A randomized double-blind trial of intravenous immunoglobulins for pemphigus","volume":"60","author":"Amagi","year":"2009","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2017.11.009_bib0350","doi-asserted-by":"crossref","first-page":"315","DOI":"10.2165\/11533290-000000000-00000","article-title":"Intravenous immunoglobulins therapy in autoimmune mucocutaneous blistering disease: A review of the evidence for its efficacy and safety","volume":"11","author":"G\u00fcrcan","year":"2010","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.ad.2017.11.009_bib0355","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.clim.2003.11.002","article-title":"A nonrandomized comparison of the clinical outcome of ocular involvement in patients with mucous membrane (cicatricial) pemphigoid between conventional immunosupressive and intravenous immunoglobulin therapies","volume":"111","author":"Letko","year":"2004","journal-title":"Clin Immunol"},{"key":"10.1016\/j.ad.2017.11.009_bib0360","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1111\/j.1468-3083.2011.04205.x","article-title":"Treatment of epidermolysis bullosa acquisita with intravenous immunoglobulin in patients non-responsive to conventional therapy: clinical outcome and post-treatment long-term follow up","volume":"26","author":"Ahmed","year":"2012","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2017.11.009_bib0365","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1111\/bjd.13633","article-title":"First-line combination therapy with rituximab and corticosteroids provides a high complete remission rate in moderate-to-severe bullous pemphigoid","volume":"173","author":"Cho","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2017.11.009_bib0370","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1111\/ced.13092","article-title":"Positive clinical outcome in a patient with recalcitrant bullous pemphigoid treated with rituximab and intravenous immunoglobulin","volume":"42","author":"Nguyen","year":"2017","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.ad.2017.11.009_bib0375","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.jaad.2015.11.030","article-title":"Treatment of recalcitrant bullous pemphigoid (BP) with a novel protocol: A retrospective study with a 6-year follow-up","volume":"74","author":"Ahmed","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2017.11.009_bib0380","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/j.jaad.2004.07.052","article-title":"Intravenous immune globulin in the treatment of persistent pemphigoid gestationis","volume":"51","author":"Kreuter","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2017.11.009_bib0385","doi-asserted-by":"crossref","first-page":"189","DOI":"10.2310\/7750.2009.09001","article-title":"Antepartum intravenous immunoglobulin therapy in refractory pemphigoid gestationis: Case report and literature review","volume":"14","author":"Doiron","year":"2010","journal-title":"J Cutan Med Surg"},{"key":"10.1016\/j.ad.2017.11.009_bib0390","doi-asserted-by":"crossref","first-page":"e269","DOI":"10.1111\/ijd.12128","article-title":"A resistant case of pemphigus gestationis successfully treated with intravenous immunoglobulin plus cyclosporine","volume":"53","author":"Hapa","year":"2014","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.ad.2017.11.009_bib0395","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.intimp.2015.02.038","article-title":"Positive clinical outcome with IVIg as monotherapy in recurrent pemphigoid gestationis","volume":"26","author":"Nguyen","year":"2015","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.ad.2017.11.009_bib0400","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.autrev.2015.04.002","article-title":"Kawaasaki disease: An evolving paradigm","volume":"14","author":"Greco","year":"2015","journal-title":"Autoinmun Rev"},{"key":"10.1016\/j.ad.2017.11.009_bib0405","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s00431-006-0223-z","article-title":"Prediction of non-responsiveness to standard high-dose gamma-globulin therapy in patients with acute Kawaasaki disease before starting initial treatment","volume":"166","author":"Sano","year":"2007","journal-title":"Eur J Pediatr"},{"key":"10.1016\/j.ad.2017.11.009_bib0410","doi-asserted-by":"crossref","first-page":"408","DOI":"10.3345\/kjp.2016.59.10.408","article-title":"Prediction of unresponsiveness to second intravenous immunoglobulin treatment in patients with Kawasaki disease refractory to initial treatment","volume":"59","author":"Seo","year":"2016","journal-title":"Korean J Pediatr"},{"key":"10.1016\/j.ad.2017.11.009_bib0415","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1111\/bjd.14530","article-title":"U.K. guidelines for the management of Steven-Johnson syndrome\/toxic epidermal necrolysis in adults 2016","volume":"174","author":"Creamer","year":"2016","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2017.11.009_bib0420","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/ddg.13013_g","article-title":"European Guidelines (S1) on the use of high-dose intravenous immunoglobulin in dermatology","volume":"15","author":"Enk","year":"2017","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1016\/j.ad.2017.11.009_bib0425","article-title":"Toxic epidermal necrolysis treatment without immunosuppressive therapy in a Burn Centre: A series of 10 cases","author":"Gacto-Sanchez","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2017.11.009_bib0430","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1067\/mjd.2000.104001","article-title":"Scleromyxedema: Response to high-dose intravenous immunoglobulin","volume":"43","author":"Lister","year":"2000","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2017.11.009_bib0435","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.ad.2011.04.015","article-title":"Escleromixedema y s\u00edndrome dermato-neuro: buena respuesta al tratamiento con glucocorticoides e inmunoglobulinas endovenosas","volume":"103","author":"Bielsa","year":"2012","journal-title":"Actas Dermatosifilogr"},{"key":"10.1016\/j.ad.2017.11.009_bib0440","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.annder.2014.04.123","article-title":"Dermato-neuro syndrome during scleromyxedema: Efficacy of plasmapheresis and intravenous immunoglobulin","volume":"141","author":"Charles","year":"2014","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.ad.2017.11.009_bib0445","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/j.1365-2230.2006.02275.x","article-title":"Intravenous immunoglobulin is effective as a sole immunomodulatory agent in pyoderma gangrenosum unresponsive to systemic corticosteroids","volume":"32","author":"Suchak","year":"2007","journal-title":"Clin Exper Dermatol"},{"key":"10.1016\/j.ad.2017.11.009_bib0450","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/j.1365-2133.2007.08217.x","article-title":"Treatment of pyoderma gangrenosum with intravenous immunoglobulin","volume":"157","author":"Cummins","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2017.11.009_bib0455","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/j.1440-0960.2008.00506.x","article-title":"Treatment of refractory pyoderma gangrenosum with intravenous immunoglobulin","volume":"50","author":"De Zwaan","year":"2009","journal-title":"Austral J Dermatol"},{"key":"10.1016\/j.ad.2017.11.009_bib0460","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1111\/dth.12233","article-title":"Pulsed intravenous immunoglobulin therapy in refractory ulcerated livedoid vasculopathy: Seven cases and a literature review","volume":"28","author":"Kim","year":"2015","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.ad.2017.11.009_bib0465","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.jaad.2014.05.039","article-title":"Efficacy of intravenous immunoglobulin in livedoid vasculopathy: Long-term follow-up of 11 patients","volume":"71","author":"Monshi","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2017.11.009_bib0470","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1111\/j.1365-4632.2012.05826.x","article-title":"Intravenous immunoglobulin in difficult-to-treat ulcerated livedoid vasculopathy: Five cases and a literature review","volume":"52","author":"Bounfour","year":"2013","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.ad.2017.11.009_bib0475","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1080\/1744666X.2017.1292134","article-title":"Dupilumab in the treatment od moderate-to-severe atopic dermatitis","volume":"13","author":"Kraft","year":"2017","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.ad.2017.11.009_bib0480","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1002\/phar.1915","article-title":"Omalizumab for the treatment of chronic idiopathic urticaria: Systematic review of the literature","volume":"37","author":"Tonacci","year":"2017","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ad.2017.11.009_bib0485","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.humimm.2005.01.022","article-title":"High dose intravenous immunoglobulins: An option in the treatment of systemic lupus erythematosus","volume":"66","author":"Toubi","year":"2005","journal-title":"Hum Immunol"},{"key":"10.1016\/j.ad.2017.11.009_bib0490","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1002\/art.20195","article-title":"Intravenous immunoglobulin modulates cutaneous involvement and reduces skin fibrosis in systemic sclerosis: An open label study","volume":"50","author":"Levy","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ad.2017.11.009_bib0495","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/S0272-6386(12)70265-2","article-title":"Treatment of antineutrophil cytoplasmic autoantibody-positive systemic vasculitis and glomerulonephritis with pooled intravenous gammaglobulin","volume":"20","author":"Tuso","year":"1992","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ad.2017.11.009_bib0500","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/0091-6749(91)90195-T","article-title":"Treatment of Churg-Strauss syndrome with high-dose intravenous immunoglobulin","volume":"88","author":"Hamilos","year":"1991","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.ad.2017.11.009_bib0505","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1159\/000051741","article-title":"Transient and partial effect of high-dose intravenous immunoglobulin in polyarteritis nodosa","volume":"203","author":"Kroiss","year":"2001","journal-title":"Dermatology"},{"key":"10.1016\/j.ad.2017.11.009_bib0510","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1111\/jdv.13725","article-title":"European Guidelines (S1) on the use of high-dose intravenous immunoglobulin in dermatology","volume":"30","author":"Enk","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2017.11.009_bib0515","first-page":"433","article-title":"Adverse events in 1395 infusions with different intravenous gammaglobulin products","volume":"73","author":"Malbr\u00e1n","year":"2013","journal-title":"Medicina (B Aires)"},{"key":"10.1016\/j.ad.2017.11.009_bib0520","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1002\/mus.23895","article-title":"Subcutaneous immunoglobulin treatment of inclusion-body myositis stabilizes dysphagia","volume":"48","author":"Pars","year":"2013","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ad.2017.11.009_bib0525","doi-asserted-by":"crossref","first-page":"426","DOI":"10.2500\/aap.2016.37.3987","article-title":"Intravenous and subcutaneous immunoglobulin G replacement therapy","volume":"47","author":"Bonilla","year":"2016","journal-title":"Allergy Asthma Proc"},{"key":"10.1016\/j.ad.2017.11.009_bib0530","first-page":"288","article-title":"Novel aspects of hypogammaglobulinemic states: Subcutaneous immunoglobulin treatment","volume":"4","author":"Grunebaum","year":"2002","journal-title":"Isr Med Assoc J"},{"key":"10.1016\/j.ad.2017.11.009_bib0535","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s13554-011-0009-3","article-title":"New frontiers in subcutaneous immunoglobulin treatment","volume":"14","author":"Jolles","year":"2011","journal-title":"Biol Ther"},{"key":"10.1016\/j.ad.2017.11.009_bib0540","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.autrev.2015.12.003","article-title":"Long-term subcutaneous immunoglobulin use in inflammatory myopathies: A retrospective review of 19 cases","volume":"15","author":"Cherin","year":"2016","journal-title":"Autoimmun Rev"}],"container-title":["Actas Dermo-Sifiliogr\u00e1ficas"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001731017306610?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001731017306610?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T01:08:05Z","timestamp":1757552885000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0001731017306610"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":54,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["S0001731017306610"],"URL":"https:\/\/doi.org\/10.1016\/j.ad.2017.11.009","relation":{},"ISSN":["0001-7310"],"issn-type":[{"value":"0001-7310","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dermatolog\u00eda e inmunoglobulinas. \u00bfA qui\u00e9n y c\u00f3mo administrarlas?","name":"articletitle","label":"Article Title"},{"value":"Actas Dermo-Sifiliogr\u00e1ficas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ad.2017.11.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 AEDV. Published by Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}